Clarus Reiterates a Buy Rating on TerrAscend Corp (TER)

By Carrie Williams

The Healthcare company, TerrAscend Corp (TERResearch Report), has received a rating update from a Wall Street analyst today. The Healthcare company, TerrAscend Corp (CNQX: TER) has just received a rating update from a Wall Street analyst.

Atkinson noted:

“We also have increased the G&A expense run-rate and softened our gross margin outlook for 2019 and 2020.”

Atkinson has an average return of 7.7% when recommending TerrAscend Corp.

According to TipRanks.com, Atkinson is ranked #471 out of 5263 analysts.

TerrAscend Corp has an analyst consensus of Moderate Buy, with a price target consensus of C$15.

Based on TerrAscend Corp’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of C$11.72 million. In comparison, last year the company had a GAAP net loss of C$5.2 million.

Terrascend Corp. produces and sells medical cannabis products. It provides support to patients through its subsidiaries, Solace Health Inc., a licensed producer of medical cannabis, TerraHealth Network Inc., a clinical support program and education platform led by health care professionals and SolaceRx, a proposed drug preparation premises for the compounding of non-cannabis formulations for a variety of institutions. The firm also offers education and support programs to physicians and patients through health care professionals. The company was founded by Basem Hanna, Vijay Sappani and Michael Nashat on March 7, 2017 and is headquartered in Mississauga, Canada.